Cargando…
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
BACKGROUND: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT(2A), sigma(2), and α(1A)-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone...
Autores principales: | Davidson, Michael, Saoud, Jay, Staner, Corinne, Noel, Nadine, Werner, Sandra, Luthringer, Elisabeth, Walling, David, Weiser, Mark, Harvey, Philip D, Strauss, Gregory P, Luthringer, Remy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077422/ https://www.ncbi.nlm.nih.gov/pubmed/35211743 http://dx.doi.org/10.1093/schbul/sbac013 |
Ejemplares similares
-
Spectral EEG sleep profiles as a tool for prediction of clinical response to antidepressant treatment
por: Macher, Jean-Paul, et al.
Publicado: (2004) -
A Bioecosystem Theory of Negative Symptoms in Schizophrenia
por: Strauss, Gregory P.
Publicado: (2021) -
Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
por: Strauss, Gregory P., et al.
Publicado: (2021) -
What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review
por: Haguiara, Bernardo, et al.
Publicado: (2021) -
Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence
por: Czobor, Pál, et al.
Publicado: (2022)